Bayland Capital

Corporate

Bayland Capital is the corporate venture capital arm of Pharmaron, investing in companies that develop innovative medicines, medical devices, and technologies.

Website

Portfolio

companies

By category

BioTech£17.0M

By location

Cambridge£17.0M

Portfolio companies

CN Bio

CN Bio develops advanced Organ-on-a-Chip systems to transform human-relevant drug discovery.

Team

Yuexing Su

Founding Partner

Recent investments

Series B23 April 2024

£17.0M

CN Bio raises £17m in Series B funding from Bayland Capital and CN Innovations to scale operations

BioTech HealthTech MedTech

The financing round was backed by Bayland Capital and founding shareholder CN Innovations to accelerate product development and commercial expansion.

"We are seeing pivotal growth across our industry, whereby drug developers are increasingly recognising the potential of OOC technology to augment, supplement and optimize their workflows."

— Paul Brooks, CEO

CN Bio—Cambridge, UK

Bayland Capital + 1 other